Overview Dividends

(EVH) Evolent Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30050B1017

Care Management, Health Plan Services, Data Analytics, Patient Engagement, AI

EVH EPS (Earnings per Share)

EPS Growth (3Y CAGR): -88.17%

EVH Revenue

Revenue Growth (3Y CAGR): 14.77%
Revenue Trend (3Y Correlation): 84.1%

Description: EVH Evolent Health

Evolent Health, Inc. is a leading provider of specialty care management services in the US, focusing on high-value areas such as oncology, cardiology, and musculoskeletal markets. Through its integrated platform, the company delivers comprehensive health plan administration and value-based business infrastructure, enabling healthcare organizations to transition towards value-based care. Evolents proprietary technology, Identifi, plays a critical role in aggregating and analyzing data, managing care workflows, and engaging patients. Additionally, the companys Machinify Auth software leverages artificial intelligence to streamline administrative processes.

By providing holistic total cost of care management, Evolent Health is well-positioned to capitalize on the growing demand for value-based care solutions. The companys expertise in health plan services, pharmacy benefits management, risk management, analytics, and reporting enables healthcare organizations to optimize their operations and improve patient outcomes. With its strong foundation in healthcare technology, Evolent Health is poised for growth as the industry continues to shift towards value-based care models.

Analyzing the , we observe that EVHs stock has experienced significant volatility, with a 52-week high of $32.97 and a low of $7.21. The current price of $8.65 is near the 20-day SMA of $8.08, indicating a potential bullish trend. However, the 200-day SMA of $14.29 suggests that the stock is still in a downtrend. Considering the , the companys market capitalization stands at $1.015 billion, with a forward P/E ratio of 22.17, indicating moderate growth expectations.

Based on the and , our forecast suggests that EVHs stock may experience a short-term bounce, potentially reaching $9.50, driven by the companys strong position in the value-based care market. However, the long-term trend remains uncertain, and the stock may face resistance around $14.29. To reach $20, Evolent Health would need to demonstrate significant growth in its revenue and earnings, potentially driven by the adoption of its Identifi and Machinify Auth platforms. A potential target price for EVH could be around $18-20, assuming the company achieves its growth objectives and the industry continues to shift towards value-based care models.

EVH Stock Overview

Market Cap in USD	1,138m
Sector	Healthcare
Industry	Health Information Services
GiC Sub-Industry	Health Care Technology
IPO / Inception	2015-06-05

EVH Stock Ratings

Growth Rating	-35.8
Fundamental	39.8%
Dividend Rating	-
Rel. Strength	-61.0
Analysts	4.57 of 5
Fair Price Momentum	7.44 USD
Fair Price DCF	-

EVH Dividends

Currently no dividends paid

EVH Growth Ratios

Growth Correlation 3m	57%
Growth Correlation 12m	-79.7%
Growth Correlation 5y	-7.1%
CAGR 5y	-6.95%
CAGR/Max DD 5y	-0.08
Sharpe Ratio 12m	0.09
Alpha	-51.30
Beta	-1.016
Volatility	59.90%
Current Volume	2093.4k
Average Volume 20d	2111.2k
Stop Loss	8.1 (-8%)

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-109.0m TTM) > 0 and > 6% of Revenue (6% = 143.9m TTM)

FCFTA -0.00 (>2.0%) and ΔFCFTA -5.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.47% (prev 0.47%; Δ -0.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.01 (>3.0%) and CFO 18.4m > Net Income -109.0m (YES >=105%, WARN >=100%)

Net Debt (623.5m) to EBITDA (37.0m) ratio: 16.86 <= 3.0 (WARN <= 3.5)

Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (115.3m) change vs 12m ago 1.03% (target <= -2.0% for YES)

Gross Margin 13.99% (prev 19.20%; Δ -5.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 90.57% (prev 82.30%; Δ 8.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.61 (EBITDA TTM 37.0m / Interest Expense TTM 29.1m) >= 6 (WARN >= 3)

Altman Z'' -1.78

(A) -0.00 = (Total Current Assets 727.9m - Total Current Liabilities 739.1m) / Total Assets 2.65b

(B) -0.32 = Retained Earnings (Balance) -845.4m / Total Assets 2.65b

(D) -0.49 = Book Value of Equity -846.0m / Total Liabilities 1.72b

Total Rating: -1.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 39.78

1. Piotroski 1.50pt = -3.50

2. FCF Yield -0.35% = -0.18

3. FCF Margin -0.26% = -0.10

4. Debt/Equity 0.91 = 2.10

5. Debt/Ebitda 23.11 = -2.50

6. ROIC - WACC -6.24% = -7.80

7. RoE -10.82% = -1.80

8. Rev. Trend 84.13% = 4.21

9. Rev. CAGR 14.77% = 1.85

10. EPS Trend data missing

11. EPS CAGR -88.17% = -2.50

What is the price of EVH shares?

As of August 13, 2025, the stock is trading at USD 8.80 with a total of 2,093,364 shares traded.
Over the past week, the price has changed by -7.37%, over one month by -22.54%, over three months by -5.48% and over the past year by -65.20%.

Is Evolent Health a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Evolent Health (NYSE:EVH) is currently (August 2025) a stock to sell. It has a ValueRay Fundamental Rating of 39.78 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EVH is around 7.44 USD . This means that EVH is currently overvalued and has a potential downside of -15.45%.

Is EVH a buy, sell or hold?

Evolent Health has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy EVH.

Strong Buy: 9
Buy: 4
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EVH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	15.3	74%
Analysts Target Price	15.1	71.4%
ValueRay Target Price	7.9	-10.8%

Last update: 2025-08-10 02:04

EVH Fundamental Data Overview

Market Cap USD = 1.14b (1.14b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 246.5m USD (last quarter)
P/E Forward = 37.4532
P/S = 0.5181
P/B = 1.1294
P/EG = -1.37
Beta = 0.815
Revenue TTM = 2.40b USD
EBIT TTM = -75.9m USD
EBITDA TTM = 37.0m USD
Long Term Debt = 647.5m USD (from longTermDebt, last quarter)
Short Term Debt = 207.0m USD (from shortTermDebt, last quarter)
Debt = 854.5m USD (Calculated: Short Term 207.0m + Long Term 647.5m)
Net Debt = 623.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.75b USD (1.14b + Debt 854.5m - CCE 246.5m)
Interest Coverage Ratio = -2.61 (Ebit TTM -75.9m / Interest Expense TTM 29.1m)
FCF Yield = -0.35% (FCF TTM -6.13m / Enterprise Value 1.75b)
FCF Margin = -0.26% (FCF TTM -6.13m / Revenue TTM 2.40b)
Net Margin = -4.54% (Net Income TTM -109.0m / Revenue TTM 2.40b)
Gross Margin = 13.99% ((Revenue TTM 2.40b - Cost of Revenue TTM 2.06b) / Revenue TTM)
Tobins Q-Ratio = -2.06 (set to none) (Enterprise Value 1.75b / Book Value Of Equity -846.0m)
Interest Expense / Debt = 1.22% (Interest Expense 10.4m / Debt 854.5m)
Taxrate = 21.0% (US default)
NOPAT = -75.9m (EBIT -75.9m, no tax applied on loss)
Current Ratio = 0.98 (Total Current Assets 727.9m / Total Current Liabilities 739.1m)
Debt / Equity = 0.91 (Debt 854.5m / last Quarter total Stockholder Equity 935.5m)
Debt / EBITDA = 23.11 (Net Debt 623.5m / EBITDA 37.0m)
Debt / FCF = -139.4 (Debt 854.5m / FCF TTM -6.13m)
Total Stockholder Equity = 1.01b (last 4 quarters mean)
RoA = -4.11% (Net Income -109.0m, Total Assets 2.65b )
RoE = -10.82% (Net Income TTM -109.0m / Total Stockholder Equity 1.01b)
RoCE = -4.59% (Ebit -75.9m / (Equity 1.01b + L.T.Debt 647.5m))
RoIC = -4.53% (NOPAT -75.9m / Invested Capital 1.68b)
WACC = 1.71% (E(1.14b)/V(1.99b) * Re(2.27%)) + (D(854.5m)/V(1.99b) * Rd(1.22%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 6.23%
Discount Rate = 2.27% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -6.13m)
Revenue Correlation: 84.13 | Revenue CAGR: 14.77%
Revenue Growth Correlation: -84.16%
EPS Correlation: N/A | EPS CAGR: -88.17%
EPS Growth Correlation: 17.47%

Additional Sources for EVH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle